Rhythm Pharmaceuticals, Inc.
NASDAQ:RYTM
60.72 (USD) • At close May 8, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 130.126 | 77.428 | 23.638 | 3.154 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 13.368 | 9.302 | 2.133 | 0.599 | 0.69 | 0.834 | 0.442 | 0.223 | 0.144 | 0 | 0 | 0 | 0 |
| Gross Profit
| 116.758 | 68.126 | 21.505 | 2.555 | -0.69 | -0.834 | -0.442 | -0.223 | -0.144 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0.897 | 0.88 | 0.91 | 0.81 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 237.957 | 134.951 | 108.63 | 104.128 | 90.45 | 109.45 | 50.337 | 22.894 | 19.594 | 7.148 | 5.28 | 18.015 | 15.678 |
| General & Administrative Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 28.08 | 9.518 | 6.311 | 3.425 | 1.213 | 3.433 | 2.46 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 144.304 | 117.532 | 92.032 | 68.486 | 46.125 | 36.55 | 28.08 | 9.518 | 6.311 | 3.425 | 1.213 | 3.433 | 2.46 |
| Other Expenses
| 0 | 0 | -0.79 | 100 | 0 | 0 | 0 | -1.863 | 0 | -0.5 | 0 | 0 | 0 |
| Operating Expenses
| 382.261 | 252.483 | 200.662 | 172.614 | 136.575 | 146 | 78.417 | 32.412 | 25.905 | 10.573 | 6.493 | 21.448 | 18.138 |
| Operating Income
| -265.503 | -184.357 | -179.157 | -170.059 | -136.575 | -146 | -78.417 | -32.412 | -25.905 | -10.573 | -6.493 | -21.448 | -18.138 |
| Operating Income Ratio
| -2.04 | -2.381 | -7.579 | -53.919 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 5.247 | 0.243 | -1.962 | 100.447 | 2.579 | 5.271 | 4.353 | -1.297 | 0.033 | -0.5 | 0 | 0.017 | 0.008 |
| Income Before Tax
| -260.256 | -184.114 | -181.119 | -69.612 | -133.996 | -140.729 | -74.064 | -33.709 | -25.872 | -11.073 | -6.493 | -21.431 | -18.13 |
| Income Before Tax Ratio
| -2 | -2.378 | -7.662 | -22.071 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0.346 | 0.564 | 1.962 | -1.605 | -3.269 | -6.105 | 4.353 | 1.074 | 0 | 0 | 0 | 0 | 0 |
| Net Income
| -260.602 | -184.678 | -183.081 | -68.007 | -130.727 | -134.624 | -74.064 | -33.709 | -25.872 | -11.073 | -6.493 | -21.431 | -18.13 |
| Net Income Ratio
| -2.003 | -2.385 | -7.745 | -21.562 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -4.21 | -3.2 | -3.51 | -1.37 | -2.96 | -3.7 | -2.39 | -2.54 | -1.55 | -0.66 | -0.64 | -0.43 | -0.36 |
| EPS Diluted
| -4.21 | -3.2 | -3.51 | -1.37 | -2.96 | -3.7 | -2.39 | -2.54 | -1.55 | -0.66 | -0.64 | -0.43 | -0.36 |
| EBITDA
| -238.09 | -168.464 | -174.515 | -68.454 | -135.885 | -145.166 | -77.975 | -32.189 | -25.761 | -10.073 | 0 | -21.411 | -18.121 |
| EBITDA Ratio
| -1.83 | -2.176 | -7.383 | -21.704 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |